Search tesamorelin for sale, and the results can look surprisingly similar.
Many listings show a vial.
Most display a milligram value.
Several highlight “99%+ purity.”
Yet the products may differ substantially.
Therefore, buyers need a comparison framework.
A review of search-visible research suppliers in August 2026 shows a wide range of commercial presentations.
One supplier lists a 10 mg research product at $120.
Another currently lists 10 mg at $79.99 and 20 mg at $124.99.
A separate supplier lists a 10 mg product at $74.99.
Another displays 5 mg material from $45.
These prices are a market snapshot, not a recommendation.
Listings and promotions can change quickly.
| Example Listing | Size | Displayed Price | Advertised Quality Feature |
|---|---|---|---|
| Supplier A | 10 mg | $120 | COA / third-party testing |
| Supplier B | 10 mg | $79.99 | 99%+ / COA |
| Supplier B | 20 mg | $124.99 | 99%+ / COA |
| Supplier C | 10 mg | $74.99 | Research-use listing |
| Supplier D | 5 mg | $45 | Lot-specific COA |
Price observations checked against supplier pages surfaced in current search results.
Suppose a laboratory needs 40 mg.
Option A costs $60 per 10 mg vial.
Option B costs $80.
At first, Option A saves $80 across four vials.
However, imagine that Option A lacks usable identity data.
The laboratory now pays for independent testing.
The apparent saving can disappear quickly.
Therefore, purchasing teams should calculate total verification cost, not only vial cost.
“99% purity” sounds precise.
However, buyers should ask how the supplier obtained that number.
Was it RP-HPLC?
Which detector did the laboratory use?
Does the report show a chromatogram?
Does the COA match the shipped lot?
FDA guidance on analytical procedure validation emphasizes fit-for-purpose analytical performance. FDA research also uses LC-MS methods to characterize peptide drugs and related impurities.
That makes analytical transparency more valuable than a large number on a product image.
| Listing Feature | Weak Evidence | Stronger Evidence |
|---|---|---|
| Purity | 99% badge | HPLC chromatogram |
| Identity | Name on vial | MS result |
| Testing | “Lab tested” | Named test + report |
| Batch | Generic COA | Lot-specific COA |
| Quantity | Label claim | Defined specification |
Purity matters.
However, the target specification depends on the project.
An analytical standard, assay-development material, and early-stage exploratory project may use different acceptance criteria.
Therefore, “highest available purity” should not replace a technical requirement.
Define the study first.
Then define the specification.
Finally, compare products.
That order keeps purchasing rational.
The official tesamorelin product provides useful context.
DailyMed states that EGRIFTA WR contains 11.6 mg of tesamorelin per vial. It is a sterile lyophilized powder and an Rx-only product.
The label specifies room-temperature storage at 20°C to 25°C, with permitted excursions from 15°C to 30°C.
However, do not transfer those storage instructions automatically to unrelated research products.
Different formulations can require different handling.
Follow the actual supplier specification for the material purchased.
Two randomized studies provide a strong evidence base for the approved molecule.
At Week 26, mean VAT changed by -18% and -14% in the two active groups.
The corresponding placebo changes were +2% and -2%.
However, the FDA-approved label also says EGRIFTA WR is not a weight-loss treatment.
A responsible tesamorelin product page should present both facts.
That approach supports scientific accuracy.
It also avoids exaggerated marketing.
A buyer finds three 10 mg listings.
Supplier X offers the lowest price.
Supplier Y provides HPLC and MS.
Supplier Z provides those records plus batch traceability and repeat-batch support.
For a one-off exploratory assay, X may look attractive.
For a long study, Z may reduce procurement risk.
Therefore, the “best” listing depends on the project.
Start with intended use. Then compare identity, purity, COA quality, lot traceability, quantity, storage, and repeat supply.
No. Ask for the supporting analytical report and the corresponding batch number.
No. EGRIFTA is an approved Rx product with a defined pharmaceutical formulation. Research products use supplier-defined specifications.
